Eli Lilly

News

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for

News

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its

News

Lilly's Verzenios gets NICE blessing for early-stage breast ...

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly's Verzenios, after new guidance from NICE backed use of the drug after surge

News

Lilly partners with Sidekick in digital health alliance

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick an

News

Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,

News

Sanofi's plans for OTC Cialis hit a snag in US

It has been eight years since Sanofi licensed rights to an over-the-counter version of erectile dysfunction (ED) drug Cialis from Eli Lilly, and the FDA has just thrown a spanner into its p

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Roche's fast-growing eye drug Vabysmo set for EU approval

Lilly's Verzenios gets NICE blessing for early-stage breast ...

Lilly partners with Sidekick in digital health alliance

Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in...

Sanofi's plans for OTC Cialis hit a snag in US

NICE changes stance on Genmab's cervical cancer drug

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks